Mar, N., Friedlander, T. W., Hoimes, C. J., Flaig, T. W., Bilen, M. A., Balar, A. V., … Milowsky, M. I. (2020). Study EV-103: New randomized cohort testing enfortumab vedotin as monotherapy or in combination with pembrolizumab in locally advanced or metastatic urothelial cancer. In JOURNAL OF CLINICAL ONCOLOGY (Vol. 38).

Mar, Nataliya, Terence W. Friedlander, Christopher J. Hoimes, Thomas W. Flaig, Mehmet Asim Bilen, Arjun Vasant Balar, Elizabeth Henry, et al. “Study EV-103: New randomized cohort testing enfortumab vedotin as monotherapy or in combination with pembrolizumab in locally advanced or metastatic urothelial cancer.” In JOURNAL OF CLINICAL ONCOLOGY, Vol. 38, 2020.

Mar N, Friedlander TW, Hoimes CJ, Flaig TW, Bilen MA, Balar AV, et al. Study EV-103: New randomized cohort testing enfortumab vedotin as monotherapy or in combination with pembrolizumab in locally advanced or metastatic urothelial cancer. In: JOURNAL OF CLINICAL ONCOLOGY. 2020.

Mar, Nataliya, et al. “Study EV-103: New randomized cohort testing enfortumab vedotin as monotherapy or in combination with pembrolizumab in locally advanced or metastatic urothelial cancer.” JOURNAL OF CLINICAL ONCOLOGY, vol. 38, no. 15, 2020.

Mar N, Friedlander TW, Hoimes CJ, Flaig TW, Bilen MA, Balar AV, Henry E, Srinivas S, Rosenberg JE, Petrylak DP, Burgess EF, Merchan JR, Tagawa ST, Carret A-S, Steinberg JL, Chaney MF, Milowsky MI. Study EV-103: New randomized cohort testing enfortumab vedotin as monotherapy or in combination with pembrolizumab in locally advanced or metastatic urothelial cancer. JOURNAL OF CLINICAL ONCOLOGY. 2020.